Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Takeda Pharmaceutical Company Limited and its subsidiary, Millennium, recently announced the submission of a new drug application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for Adcetris (brentuximab vedotin).

Takeda is looking to get Adcetris approved in Japan for the treatment of adults suffering from relapsed or refractory CD30 positive Hodgkin lymphoma (HL) and relapsed or refractory CD30 positive anaplastic large cell lymphoma (ALCL).

The regulatory application was based on results from a pivotal phase I/II study that evaluated the safety, tolerability and efficacy of Adcetris in patients suffering from relapsed or refractory CD30 positive HL and relapsed or refractory CD30 positive systemic ALCL. The company’s submission also included data from two global pivotal phase II studies.

We note that Adcetris enjoys orphan drug status in Japan for HL and ALCL.

Adcetris has been jointly developed by Seattle Genetics Inc. (SGEN - Snapshot Report) and Millennium. Adcetris is currently approved in both the US and the EU.

Adcetris is approved in the US for the treatment of patients infected with HL after unsuccessful autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in non-ASCT patients and also for the treatment of patients with sALCL after failure of at least one multi-agent chemotherapy regimen.

Seattle Genetics recently submitted a supplemental Biologics License Application (sBLA) seeking FDA approval for Adcetris for retreatment and extended duration beyond 16 cycles of therapy in relapsed HL and sALCL patients.

In the EU, Adcetris received conditional marketing authorization for the treatment of adults with relapsed or refractory CD 30+HL after ASCT or after a minimum of two prior therapies when ASCT or multi-agent chemotherapy is inappropriate. It is also approved for the treatment of relapsed or refractory sALCL in adults.

Currently, Takeda carries a Zacks Rank #4 (Sell). Comparatively, Lannett Company, Inc. (LCI - Snapshot Report)  and Cytokinetics, Inc. (CYTK - Snapshot Report) look better-positioned than Takeda. They both carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%